ALVR INVESTORS: Lead Plaintiff Deadline is Approaching; Contact Robbins LLP for Information About Your Rights
March 06, 2024 18:17 ET
|
Robbins LLP
AlloVir, Inc. (ALVR) Allegedly Misled Investors Regarding Efficacy of its posoleucel Phase 3 Studies
AlloVir, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline
March 04, 2024 17:37 ET
|
Portnoy Law
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 04, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AlloVir, Inc. (“AlloVir or the...
AlloVir, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline
February 28, 2024 01:06 ET
|
Portnoy Law
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Feb. 28, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AlloVir, Inc. (“AlloVir” or...
ALVR Shareholders Who Lost Money Should Contact Robbins LLP for Information About the AlloVir, Inc. Class Action
February 10, 2024 00:49 ET
|
Robbins LLP
AlloVir, Inc. (ALVR) Allegedly Misled Investors Regarding Efficacy of its posoleucel Phase 3 Studies
AlloVir, Inc. (ALVR) Stockholder News: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in AlloVir, Inc. Class Action
January 29, 2024 19:45 ET
|
Robbins LLP
AlloVir, Inc. (ALVR) Allegedly Misled Investors Regarding Efficacy of its posoleucel Phase 3 Studies